Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump

Novo Holdings , a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate? System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first FDA approval for the Elevate? System in patients undergoing high-risk percutaneous coronary interventions (HR-PCI).?

In connection with the financing, Eric Snyder, Partner in the Novo Holdings Venture Investments team, will join the Magenta Medical Board of Directors.?

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs?

Xeltis , a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announced on Tuesday that it has appointed Shawn Gage as its new Vice President of US Clinical Affairs.?

Gage brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access and will lead the Company’s US pivotal trial strategy following recent IDE approval.?

Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma?

Ariceum Therapeutics a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, on Thursday announced that it has commenced a Phase 1 first-in-human clinical trial (CITADEL-123) of?123I-ATT001, its Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma. Ariceum is the first company to sponsor a clinical trial of Auger therapy for recurrent glioblastoma, an aggressive form of brain cancer with a high unmet medical need.?

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis?

Calliditas Therapeutics announced that its Phase 2b TRANSFORM trial had met its primary endpoint in primary biliary cholangitis, a chronic, orphan, autoimmune disease of the liver’s bile ducts. The TRANSFORM trial – a double-blind, randomized, placebo-controlled Phase 2b study – demonstrated that patients given setanaxib showed statistically significant improvements in the primary endpoint of Alkaline Phosphatase (ALP), compared to those given a placebo.??

Check out our podcast interview with Dr Ruth McKernan CBE: Neuroscientist, businesswoman and innovation leader?

In the latest episode of our podcast, Optimum’s Eva Haas discusses the incredible career highlights of Dr Ruth McKernan CBE , of SV Health Investors & AstronauTx , including the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer’s?in recent years.?

Sign up to our 16th Annual Healthcare Investor Conference, featuring our amazing panel on ‘How to build European champions’?

With less than three months to go, the countdown to Optimum’s 16th Annual Healthcare Investor Conference has officially begun… and what better way to celebrate than the announcement of our ‘Scaling up - How to build European champions’ panel!??

Chaired by Simon Aimes, Partner, Cooley??

• Renee Lucander-Aguilar, Chief Executive Officer, Calliditas Therapeutics?

• Geraldine O’Keeffe, Partner, EQT Group?

• Kieran Murphy, Chairman, Gamma Biosciences & SPT Labtech??

• Hakan Goker, Managing Director, M Ventures.?

If you would like to join us on Thursday the 10th of October to hear top tips from key industry executives on how to build life science success in Europe, register your interest in attending today. The conference is by invitation only and places are limited.??

Optimum's 16th Annual Healthcare Investor Conference is kindly sponsored by, Citi, Cooley LLP, Intermediate Capital Group (ICG), Nasdaq & The Babraham Institute.

That’s all folks! We hope you are enjoying Optimum’s weekly round-ups;?subscribe?today so you never miss an edition.?